Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing ...

Shares of Tiziana Life Sciences (NASDAQ:TLSA) jumped 12% Thursday after the company said that a study of its drug candidate ...

The following is a summary of “Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V ...

The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent ...

About 45% of children who receive intranasal midazolam for laceration repair do not respond to the medication and demonstrate ...

Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

Objective: To characterize the pharmacokinetic-pharmacodynamic correlation of intranasal and intravenous fentanyl in opioid-naïve patients undergoing third molar extraction. Methods: A double ...

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...

AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic Paul Goepfert, MD, Director for ...

The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent ...